These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1025 related items for PubMed ID: 22559167

  • 21. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
    Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P.
    Mol Cancer; 2010 Sep 22; 9():256. PubMed ID: 20860815
    [Abstract] [Full Text] [Related]

  • 22. EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis.
    Liu X, Gao X, Yang Y, Yang D, Guo Q, Li L, Liu S, Cong W, Lu S, Hou L, Wang B, Li N.
    Apoptosis; 2024 Aug 22; 29(7-8):1161-1184. PubMed ID: 38743191
    [Abstract] [Full Text] [Related]

  • 23. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 22; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 24. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
    Hui IC, Tung EK, Sze KM, Ching YP, Ng IO.
    Liver Int; 2010 Jan 22; 30(1):65-75. PubMed ID: 19845851
    [Abstract] [Full Text] [Related]

  • 25. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.
    Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, Cheng AL.
    J Biol Chem; 2009 Apr 24; 284(17):11121-33. PubMed ID: 19261616
    [Abstract] [Full Text] [Related]

  • 26. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY.
    Clin Cancer Res; 2008 Aug 15; 14(16):5124-30. PubMed ID: 18698030
    [Abstract] [Full Text] [Related]

  • 27. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
    Li T, Dong ZR, Guo ZY, Wang CH, Zhi XT, Zhou JW, Li DK, Chen ZT, Chen ZQ, Hu SY.
    Liver Int; 2015 Apr 15; 35(4):1416-29. PubMed ID: 25066210
    [Abstract] [Full Text] [Related]

  • 28. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L, Zhan Y, Wu Z, Lin M, Jin X, Jiang L, Qiu Y.
    Biomed Pharmacother; 2020 May 15; 125():110033. PubMed ID: 32187962
    [Abstract] [Full Text] [Related]

  • 29. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.
    Jasinghe VJ, Xie Z, Zhou J, Khng J, Poon LF, Senthilnathan P, Glaser KB, Albert DH, Davidsen SK, Chen CS.
    J Hepatol; 2008 Dec 15; 49(6):985-97. PubMed ID: 18930332
    [Abstract] [Full Text] [Related]

  • 30. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C.
    J Hepatol; 2012 Jan 15; 56(1):176-83. PubMed ID: 21835141
    [Abstract] [Full Text] [Related]

  • 31. Ophiopogonin‑B targets PTP1B to inhibit the malignant progression of hepatocellular carcinoma by regulating the PI3K/AKT and AMPK signaling pathways.
    Yuan F, Gao Q, Tang H, Shi J, Zhou Y.
    Mol Med Rep; 2022 Apr 15; 25(4):. PubMed ID: 35169857
    [Abstract] [Full Text] [Related]

  • 32. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
    Wang H, Zhang C, Xu L, Zang K, Ning Z, Jiang F, Chi H, Zhu X, Meng Z.
    Oncotarget; 2016 Apr 12; 7(15):20193-208. PubMed ID: 26958938
    [Abstract] [Full Text] [Related]

  • 33. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF.
    Breast Cancer Res; 2012 Apr 26; 14(2):R68. PubMed ID: 22537901
    [Abstract] [Full Text] [Related]

  • 34. Parecoxib inhibits tumorigenesis and angiogenesis in hepatocellular carcinoma through ERK-VEGF/MMPs signaling pathway.
    Tian L, Huang Y, Liu Y, Liu J, Liu Y.
    IUBMB Life; 2024 Nov 26; 76(11):972-986. PubMed ID: 38873890
    [Abstract] [Full Text] [Related]

  • 35. Baohuoside-1 targeting mTOR inducing apoptsis to inhibit hepatocellular carcinoma proliferation, invasion and migration.
    Guo Y, Zhu H, Weng M, Chen B, Wang C, Sun L.
    Biomed Pharmacother; 2020 Aug 26; 128():110366. PubMed ID: 32526459
    [Abstract] [Full Text] [Related]

  • 36. Oxaliplatin-rapamycin combination was superior to mono-drug in treatment of hepatocellular carcinoma both in vitro and in vivo.
    Li XZ, Sun YL, Cao LQ, Li MJ.
    Neoplasma; 2016 Aug 26; 63(6):880-887. PubMed ID: 27565326
    [Abstract] [Full Text] [Related]

  • 37. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y, Yan H, Frost P, Gera J, Lichtenstein A.
    Mol Cancer Ther; 2005 Oct 26; 4(10):1533-40. PubMed ID: 16227402
    [Abstract] [Full Text] [Related]

  • 38. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
    Lin XM, Hu L, Gu J, Wang RY, Li L, Tang J, Zhang BH, Yan XZ, Zhu YJ, Hu CL, Zhou WP, Li S, Liu JF, Gonzalez FJ, Wu MC, Wang HY, Chen L.
    Gastroenterology; 2017 Apr 26; 152(5):1187-1202. PubMed ID: 28065789
    [Abstract] [Full Text] [Related]

  • 39. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W, Chen J, Chuang M, Jiang D.
    APMIS; 2012 Mar 26; 120(3):195-203. PubMed ID: 22339676
    [Abstract] [Full Text] [Related]

  • 40. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
    Zhou Y, Zhang M, Zhang Z, Jia Y, Zhang C, Peng L.
    Biomed Pharmacother; 2020 Sep 26; 129():109851. PubMed ID: 32559627
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.